#1 Clinical Trials Search in Europe

Tioguanine

This article examines the use of Tioguanine (also known as 6-thioguanine or 6-TG) in various clinical trials for treating different types of cancer, particularly leukemia and lymphoma. Tioguanine is being studied in combination with other chemotherapy drugs to potentially improve outcomes for patients with relapsed or refractory cancers. The trials aim to determine the safety, efficacy, and optimal dosing of Tioguanine-based regimens.

Table of Contents

What is Tioguanine?

Tioguanine, also known as 6-thioguanine (6-TG), is a medication used in the treatment of various blood cancers and other conditions. It belongs to a class of drugs called antimetabolites, which work by interfering with the growth of cancer cells[5]. Tioguanine is available in oral tablet form and is sometimes referred to by its brand name, Thioguanine Tabloid[8].

What Conditions Does Tioguanine Treat?

Tioguanine is primarily used to treat several types of blood cancers and related conditions, including:

  • Acute Lymphoblastic Leukemia (ALL): A type of cancer that affects the white blood cells in the bone marrow[4]
  • Acute Myeloid Leukemia (AML): A cancer of the blood and bone marrow that affects myeloid cells[1]
  • Lymphoblastic Lymphoma: A type of non-Hodgkin lymphoma that primarily affects young people[8]
  • Langerhans Cell Histiocytosis (LCH): A rare disorder that causes an excess of immune cells to build up in various parts of the body[7]

How Does Tioguanine Work?

Tioguanine works by interfering with the DNA of cancer cells. When the body processes tioguanine, it is converted into active compounds called thioguanine nucleotides (TGN). These TGN can be incorporated into the DNA of rapidly dividing cells, such as cancer cells, instead of the normal building blocks of DNA. This incorporation causes problems with DNA replication and can lead to cell death[4].

In simpler terms, tioguanine acts like a “trick” building block that cancer cells mistakenly use when trying to make copies of themselves. This mistake ultimately leads to the death of the cancer cells.

How is Tioguanine Administered?

Tioguanine is typically given as an oral medication. The dosage and schedule can vary depending on the specific condition being treated and the overall treatment plan. Some common administration methods include:

  • Daily doses, often ranging from 60-80 mg/m² (milligrams per square meter of body surface area)[1]
  • Short courses of 2-3 weeks as part of a larger treatment regimen[5]
  • Low doses added to other medications during maintenance therapy[4]

It’s important to note that tioguanine is often used in combination with other chemotherapy drugs as part of a comprehensive treatment plan. Your healthcare provider will determine the best dosage and schedule for your specific situation.

Potential Side Effects

Like all medications, tioguanine can cause side effects. Some potential side effects include:

  • Bone marrow suppression: This can lead to a decrease in blood cell counts, increasing the risk of infection, anemia, and bleeding[5]
  • Liver toxicity: Tioguanine can affect liver function, so regular monitoring of liver enzymes is important[4]
  • Gastrointestinal issues: Nausea, vomiting, and loss of appetite may occur[5]
  • Sinusoidal Obstruction Syndrome (SOS): A rare but serious liver condition that can occur with long-term use[4]

Your healthcare team will monitor you closely for these and other potential side effects throughout your treatment.

Current Research and Clinical Trials

Ongoing research is exploring new ways to use tioguanine more effectively and safely. Some current areas of study include:

  • Combination therapies: Researchers are investigating how tioguanine works in combination with other drugs to improve treatment outcomes for various blood cancers[1]
  • Personalized dosing: Studies are looking at how to optimize tioguanine dosing based on individual patient characteristics and genetic factors[4]
  • Extended use in maintenance therapy: Some trials are exploring the benefits of adding low-dose tioguanine to standard maintenance therapy for leukemia[4]
  • Treatment of relapsed or refractory cancers: Tioguanine is being studied as part of treatment regimens for patients whose cancer has returned or not responded to initial treatments[1]

These ongoing studies aim to improve the effectiveness of tioguanine while minimizing its side effects, potentially leading to better outcomes for patients with blood cancers and related conditions.

Aspect Details
Drug Name Tioguanine (6-thioguanine, 6-TG)
Cancer Types Studied Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Lymphoblastic Lymphoma, Hodgkin’s Disease
Patient Population Adults, adolescents, and children with relapsed or refractory disease
Administration Oral tablet or liquid, various dosing schedules
Combination Therapies Often combined with other chemotherapy drugs (e.g., methotrexate, mercaptopurine, asparaginase)
Key Objectives Determine safety, efficacy, optimal dosing, pharmacokinetics, impact on minimal residual disease
Outcome Measures Complete response rates, event-free survival, overall survival, toxicity profiles
Notable Side Effects Bone marrow suppression, liver toxicity, increased infection risk
Ongoing Research Exploring individualized dosing strategies, combination with novel agents, use in maintenance therapy

FAQ

  • What is Tioguanine and how does it work? Tioguanine, also known as 6-thioguanine or 6-TG, is a chemotherapy drug that interferes with cancer cell DNA, causing the cells to die. It is converted into active metabolites in the body that can be incorporated into DNA, disrupting cell division and growth.
  • What types of cancer is Tioguanine being studied for? Tioguanine is being investigated in clinical trials for various blood cancers, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), lymphoblastic lymphoma, and Hodgkin's disease. It is often studied in patients with relapsed or refractory disease.
  • How is Tioguanine typically administered in these trials? In most trials, Tioguanine is given orally as a tablet or liquid. The dosage and schedule vary between studies, but it is often given daily for a set number of days as part of a chemotherapy regimen. Some trials are exploring different dosing strategies to optimize its effectiveness.
  • What are some common side effects of Tioguanine? Common side effects of Tioguanine can include bone marrow suppression (lowered blood cell counts), liver toxicity, nausea, and increased risk of infections. The trials closely monitor patients for these and other adverse effects to determine the drug's safety profile.
  • Are there any promising results from Tioguanine clinical trials so far? While specific results vary between trials, some studies have shown that Tioguanine-containing regimens can be effective in achieving remission in certain patients with relapsed or refractory leukemias and lymphomas. However, more research is needed to fully determine its efficacy and optimal use in different cancer types and patient populations.

Ongoing Clinical Trials on Tioguanine

  • Study of Ruxolitinib and Chemotherapy Drug Combination for Children with Acute Lymphoblastic Leukemia and JAK/STAT Pathway Activation

    Recruiting

    1 1 1 1
    Investigated drugs:
    Poland

  • Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +13

  • Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Estonia Finland France Germany +8

  • Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +5

  • Study on the Safety and Effectiveness of Atezolizumab with Thiopurine Therapy for Patients with Advanced or Metastatic Solid Tumors

    Not recruiting

    1 1 1
    Investigated drugs:
    Denmark

  • Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +6

  • Study on Acute Lymphoblastic Leukemia Treatment in Children and Adolescents Using Bortezomib, Blinatumomab, and Methotrexate Combination

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Poland

Glossary

  • Acute Lymphoblastic Leukemia (ALL): A type of blood cancer that affects the lymphoid cells in the bone marrow, causing rapid growth of abnormal white blood cells.
  • Acute Myeloid Leukemia (AML): A cancer of the blood and bone marrow characterized by rapid growth of abnormal myeloid cells that interfere with normal blood cell production.
  • Lymphoblastic Lymphoma: A type of non-Hodgkin lymphoma that affects lymphoblasts, which are immature white blood cells.
  • Relapsed: The return of cancer after a period of improvement or remission.
  • Refractory: Cancer that does not respond to treatment or stops responding after initial improvement.
  • Remission: A decrease or disappearance of signs and symptoms of cancer in response to treatment.
  • Maintenance Therapy: Treatment given to help keep cancer from coming back after it has responded to initial therapy.
  • Minimal Residual Disease (MRD): Small numbers of cancer cells that remain in the body during or after treatment, often detectable only by highly sensitive tests.
  • Event-Free Survival (EFS): The length of time after treatment during which no specified adverse events (such as relapse or death) occur in a group of people with cancer.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Thiopurine Methyltransferase (TPMT): An enzyme involved in the metabolism of thiopurine drugs like Tioguanine, which can affect drug effectiveness and toxicity.
  • DNA-TG: Thioguanine nucleotides incorporated into DNA, which is a measure of Tioguanine's effectiveness and potential toxicity.
  • Sinusoidal Obstruction Syndrome (SOS): A potentially serious liver complication that can occur as a side effect of certain chemotherapy drugs.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.

References

  1. https://clinicaltrials.gov/study/NCT06351306
  2. https://clinicaltrials.gov/study/NCT02141100
  3. https://clinicaltrials.gov/study/NCT00504660
  4. https://clinicaltrials.gov/study/NCT02912676
  5. https://clinicaltrials.gov/study/NCT00439296
  6. https://clinicaltrials.gov/study/NCT00587873
  7. https://clinicaltrials.gov/study/NCT00588536
  8. https://clinicaltrials.gov/study/NCT00866749
  9. https://clinicaltrials.eu/trial/study-on-tioguanine-and-drug-combination-for-patients-aged-0-45-with-newly-diagnosed-acute-lymphoblastic-leukemia/
  10. https://clinicaltrials.gov/study/NCT00005596